Cargando…

New PD-L1 inhibitors in non-small cell lung cancer – impact of atezolizumab

The era of immunotherapy has changed the face of how we approach treatment for many oncologic and hematologic malignancies. Lung cancer has been in the forefront of checkpoint inhibition for the past 2 years and has paved the path for other subspecialties. While PD-1 inhibitors nivolumab and pembrol...

Descripción completa

Detalles Bibliográficos
Autores principales:	Seetharamu, Nagashree, Preeshagul, Isabel R, Sullivan, Kevin M
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2017
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5516873/ https://www.ncbi.nlm.nih.gov/pubmed/28761384 http://dx.doi.org/10.2147/LCTT.S113177

Ejemplares similares

Optimizing Tissue Use: A Step-wise Approach to Diagnosing Squamous Cell Lung Carcinoma on Small Biopsies
por: Olazagasti, Coral, et al.
Publicado: (2020)

Simple parameters to solve a complex issue: predicting response to checkpoint inhibitor therapy in lung cancer
por: Newman, James, et al.
Publicado: (2020)

A Comprehensive Review of Contemporary Literature for Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer and Their Toxicity
por: Lee, Chung-Shien, et al.
Publicado: (2020)

Profile of Capmatinib for the Treatment of Metastatic Non-Small Cell Lung Cancer (NSCLC): Patient Selection and Perspectives
por: Fraser, Madison, et al.
Publicado: (2023)

Disparities in lung cancer screening rates among the Hispanic/LatinX population
por: Olazagasti, Coral, et al.
Publicado: (2021)

Disparities in Lung Cancer Screening in Puerto Rico: A United States Colony with Unequal Benefits
por: Olazagasti, Coral, et al.
Publicado: (2021)

Lung cancer screening guidelines are clear but are they being followed?
por: Olazagasti, Coral, et al.
Publicado: (2020)

Pretreatment nutritional status and response to checkpoint inhibitors in lung cancer
por: Lee, Chung-Shien, et al.
Publicado: (2020)

Impact of Family and Social Network on Tobacco Cessation Amongst Cancer Patients
por: Neumann, Melissa, et al.
Publicado: (2021)

Epidemiology and clinicopathological features of lung cancer in patients with prior history of breast cancer
por: Wang, Kevin Y, et al.
Publicado: (2021)

One size does not fit all: Evaluating disparities in lung cancer screening eligibility amongst the Hispanic population
por: Olazagasti, Coral, et al.
Publicado: (2022)

Osimertinib in EGFR-Mutated Lung Cancer: A Review of the Existing and Emerging Clinical Data
por: Lee, Chung-Shien, et al.
Publicado: (2021)

Cost–effectiveness of adjuvant atezolizumab for patients with stage II–IIIA PD-L1+ non-small-cell lung cancer
por: Das, Millie, et al.
Publicado: (2023)

Implementing physician education to increase lung cancer screening uptake
por: Olazagasti, Coral, et al.
Publicado: (2023)

Phase II study of atezolizumab with bevacizumab for non-squamous non-small cell lung cancer with high PD-L1 expression (@Be Study)
por: Seto, Takashi, et al.
Publicado: (2022)

Use of Atezolizumab for Bladder and Non–Small Cell Lung Cancers
por: Moore, Kayla Faith
Publicado: (2017)

An Atypical Presentation of Lichen Planus-Like Reaction from Pembrolizumab
por: Lee, Matthew, et al.
Publicado: (2019)

Missed Opportunities? An Observational Analysis of Lung Cancer Screening Utilization Amongst Patients With Lung Cancer
por: Olazagasti, Coral, et al.
Publicado: (2022)

Cost-effectiveness of atezolizumab versus pembrolizumab as first-line treatment in PD-L1-positive advanced non-small-cell lung cancer in Spain
por: Isla, Dolores, et al.
Publicado: (2023)

Atezolizumab, a PD-L1 Inhibitor: An Association of Bleeding Gastric Ulcer With Its Use
por: Bapatla, Anusha, et al.
Publicado: (2021)

Evaluating of HPV–DNA ISH as an adjunct to p16 testing in oropharyngeal cancer
por: Chi, Jeffrey, et al.
Publicado: (2020)

Structural basis of the therapeutic anti-PD-L1 antibody atezolizumab
por: Zhang, Fei, et al.
Publicado: (2017)

A PK/PD Analysis of Circulating Biomarkers and Their Relationship to Tumor Response in Atezolizumab‐Treated non‐small Cell Lung Cancer Patients
por: Netterberg, Ida, et al.
Publicado: (2018)

Cost-Effectiveness Analysis of Atezolizumab Versus Chemotherapy as First-Line Treatment for Metastatic Non-Small-Cell Lung Cancer With Different PD-L1 Expression Status
por: Liu, Guoqiang, et al.
Publicado: (2021)

C-reactive protein reduction post treatment is associated with improved survival in atezolizumab (anti-PD-L1) treated non-small cell lung cancer patients
por: Patil, Namrata S., et al.
Publicado: (2021)

Molecular mechanism of PD-1/PD-L1 blockade via anti-PD-L1 antibodies atezolizumab and durvalumab
por: Lee, Hyun Tae, et al.
Publicado: (2017)

SAT-LB102 When the Answer Is Not in the First Look: An Unusual Presentation of Follicular Thyroid Carcinoma
por: Bernabe Ramirez, Carolina, et al.
Publicado: (2019)

The impact of immune-inflammation-nutritional parameters on the prognosis of non-small cell lung cancer patients treated with atezolizumab
por: Matsubara, Taichi, et al.
Publicado: (2020)

Impact of smoking on efficacy of PD-1/PD-L1 inhibitors in non-small cell lung cancer patients: a meta-analysis
por: Li, Bingjia, et al.
Publicado: (2018)

Impact of losing adipose tissue on outcomes from PD‐1/PD‐L1 inhibitor monotherapy in non‐small cell lung cancer
por: Nishioka, Naoya, et al.
Publicado: (2022)

Clinical impact of tumour burden on the efficacy of PD‐1/PD‐L1 inhibitors plus chemotherapy in non‐small‐cell lung cancer
por: Miyawaki, Taichi, et al.
Publicado: (2022)

PD-1/PD-L1 inhibitors as a hope for smokers of non-small cell lung cancer patient
por: Yu, Zhuo, et al.
Publicado: (2019)

Oligoprogressive Non-Small-Cell Lung Cancer under Treatment with PD-(L)1 Inhibitors
por: Rheinheimer, Stephan, et al.
Publicado: (2020)

The European Medicines Agency review of the initial application of atezolizumab and the role of PD-L1 expression as biomarker for checkpoint inhibitors
por: Araujo-Fernandez, I., et al.
Publicado: (2020)

Profile of atezolizumab in the treatment of metastatic non-small-cell lung cancer: patient selection and perspectives
por: Facchinetti, Francesco, et al.
Publicado: (2018)

Comutations in DDR Pathways Predict Atezolizumab Response in Non-Small Cell Lung Cancer Patients
por: Xiong, Anning, et al.
Publicado: (2021)

Safety and clinical activity of atezolizumab plus erlotinib in patients with non-small-cell lung cancer
por: Rudin, C.M., et al.
Publicado: (2023)

Pneumonitis in Non-Small Cell Lung Cancer Patients Receiving Atezolizumab Post Chemo-Radiation
por: Saade, Lili Jose, et al.
Publicado: (2023)

Case Report: Replacement of PD-1 inhibitors with PD-L1 inhibitors in the treatment of squamous non-small-cell lung carcinoma
por: Wu, Tong, et al.
Publicado: (2023)

Association of immune-related pneumonitis with the efficacy of PD-1/PD-L1 inhibitors in non-small cell lung cancer
por: Cui, Pengfei, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_03r496je3s2bp52n4fniaoqe42